IDYA (IDEAYA Biosciences) Tax Provision: $0.0 Mil (TTM As of Mar. 2026)


IDYA IDEAYA Biosciences Inc IDYA
54 GF Score
Price $37.66
GF Value $205.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IDEAYA Biosciences Tax Provision?

IDEAYA Biosciences IDYA +4.12% 54 Tax Provision is $0.0 Mil as of Mar. 2026. GuruFocus rates IDYA with a GF Score™ of 54/100 and a GF Value™ of $205.30 (Possible Value Trap). The stock has 6 warning signs investors should review.

IDEAYA Biosciences's tax provision for the three months ended in Mar. 2026 was $0.0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

IDEAYA Biosciences Tax Provision Historical Data

* Premium members only.

The historical data trend for IDEAYA Biosciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEAYA Biosciences Tax Provision Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

IDEAYA Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IDYA
54GF Score
IDEAYA Biosciences Inc IDYA
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEAYA Biosciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $0.0 Mil mean?
IDEAYA Biosciences (IDYA) has a Tax Provision of $0.0 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on IDEAYA Biosciences and its competitors.
Is IDEAYA Biosciences' Tax Provision too high?
IDEAYA Biosciences' current Tax Provision is $0.0 Mil. Overall, IDEAYA Biosciences has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Tax Provision compare to PBLS and ELVN?
IDEAYA Biosciences' Tax Provision of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current Tax Provision is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $205.30, compared to a current price of $37.66 — trading 81.7% below its estimated fair value. The current Tax Provision is $0.0 Mil. IDEAYA Biosciences' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Tax Provision is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEAYA Biosciences (IDYA) Overvalued in 2026?

Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued. The current stock price of $37.66 is trading 81.7% below its estimated GF Value™ of $205.30. GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.

Key valuation signals for IDYA:

  • Tax Provision: $0.0 Mil
  • GF Value™: $205.30 vs. price of $37.66 (81.7% below fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEAYA Biosciences Business Description

Other Exchanges 30J:Germany
Address 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
54GF Score

Get the complete analysis for IDYA

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.66
Price
$205.30
GF Value